Benzinga's Small Cap Movers for Friday November 30, 2012
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of Response Genetics (NASDAQ: RGDX), the Los Angeles, CA CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer, rose 12% Friday on 5 times average volume.
Response Genetics announced Thursday that Thomas A. Bologna, Chairman and CEO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York at 2:30 PM ET on Tuesday, December 4, 2012.
Response Genetics closed at $1.38 on Friday.
Shares of Mitel Networks (NASDAQ: MITL), the Ottawa, ON provider of business communications and collaboration software and services, rose 29% Friday on 12 times average volume.
Mitel announced Thursday, financial results for the second quarter of fiscal 2013 ended October 31, 2012. Non-GAAP net income from continuing operations for the second quarter of fiscal 2013 was $14.2 million, or $0.25 per share, up from $12.6 million, or $0.23 per share, in the same period last year.
Revenue from continuing operations for the second quarter of fiscal 2013 was $145.5 million, compared to $154.6 million for the second quarter of fiscal 2012.
Mitel Networks closed at $3.31 on Friday.
Christopher & Banks
Shares of Christopher & Banks (NYSE: CBK), the Plymouth, MN company specializing in women's apparel, rose 24% Friday on 7 times average volume.
Christopher & Banks reported Thursday, results for the quarter ending October 27, 2012. For the third quarter of fiscal 2012, the Company reported net sales of $117.3 million, operating income of $3.6 million and net income of $0.10 per diluted share, the first comparable period quarterly profit in ten quarters.
Same store sales increased 13.7% in the third quarter of fiscal 2012, as compared to the comparable period last year
Christopher & Banks closed at $4.57 on Friday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.